Sign up to save your podcasts
Or
Share Talking the Cure: Discussing COVID-19’s impact on FDA’s inspection program and next steps after the pandemic
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Talking the Cure: Discussing COVID-19’s impact on FDA’s inspection program and next steps after the pandemic
In this episode, Phil Katz and Jim Johnson continue their conversation about the impact of COVID-19 on FDA’s drug inspection program and the steps companies should take now and in preparation for when the pandemic is coming to an end.
For all updates around COVID-19, visit our COVID-19 hub.
You can find additional thought leadership and information regarding Medical Devices and Technology Regulatory on HL Engage.
If you are interested in more information all around Life Sciences and Health Care, follow us on LinkedIn and Twitter.
View all episodes
By Hogan LovellsIn this episode, Phil Katz and Jim Johnson continue their conversation about the impact of COVID-19 on FDA’s drug inspection program and the steps companies should take now and in preparation for when the pandemic is coming to an end.
For all updates around COVID-19, visit our COVID-19 hub.
You can find additional thought leadership and information regarding Medical Devices and Technology Regulatory on HL Engage.
If you are interested in more information all around Life Sciences and Health Care, follow us on LinkedIn and Twitter.